RNS Number : 2146H

EKF Diagnostics Holdings PLC

05 April 2022

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Purchase of Own Shares

Further to the confirmation of its intention to implement a share buyback programme, as set out in its announcement on 29 March 2022 , the Company announces that it has purchased a total of 1,000,000 of its ordinary shares at a price of 42.55 pence per share. The ordinary shares purchased will be held in treasury.

Aggregated information

 Date of purchase                       4 April 2022 
 Number of ordinary shares purchased    1,000,000 
 Highest price paid per share           42.55 
 Lowest price paid per share            42.55 
 Volume weighted average price 
  paid                                  42.55 

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) , a detailed breakdown of individual trades is available below:

 Number of ordinary   Transaction price   Time of transaction   Trading venue 
  shares purchased     (GBp) 
 1,000,000            42.55               14:45:44              AIMX 
                     ------------------  --------------------  -------------- 

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 463,930,564 ordinary shares of 1 pence each ("Ordinary Shares") each carrying one voting right, of which 5,950,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 457,980,564. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

        EKF Diagnostics Holdings plc                                    www.ekfdiagnostics.com 
         Mike Salter, CEO                                                      via Walbrook PR 
         Marc Davies, CFO 
        Singer Capital Markets (Nominated Adviser 
         and Joint Broker) 
         Aubrey Powell / George Tzimas / Tom 
         Salvesen                                                          +44 (0)20 7496 3000 
        Investec Bank plc (Joint Broker) 
         Gary Clarence / Daniel Adams                                      +44 (0)20 7597 4000 
        Walbrook PR Limited                          +44 (0)20 7933 8780 or ekf@walbrookpr.com 
         Paul McManus / Lianne Applegarth                           Mob: +44 (0)7980 541 893 / 
                                                                           +44 (0)7584 391 303 
       About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com 
       EKF is a leading global diagnostics business with custom manufacturing 
       facilities across sites in the US, UK and Europe for a variety 
       of life science products. EKF is focussed on the following 
        Point-of-Care            Providing a portfolio Point-of-Care analysers 
                                  and consumables, particularly for use in the 
                                  area of Hematology and Diabetes, for use in 
                                  hospital and research laboratories, doctor's 
                                  offices, blood banks and for in-field anaemia 
                                  screening programmes. EKF has an estimated 80,000 
                                  hemoglobin, hematocrit, HbA1c, glucose and lactate 
                                  analysers in regular use across more than 100 
        Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                                  Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor, 
                                  Glycates Albumin, Glycated Serum Protein, Nitro-tab, 
        Life Sciences            Enzyme fermentation, Custom products and Bulk 
        Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                                  labelling, Molecular and forensic kits 
        Laboratory Services      In September 2021, EKF completed the acquisition 
                                  of Advanced Diagnostic Laboratory LLC ("ADL 
                                  Health") , a Texas based testing laboratory 
                                  certified under the Clinical Laboratory Improvement 
                                  Amendments ("CLIA") for high complexity testing. 
                                  The laboratory provides testing for a variety 
                                  of clinical, forensic and microbiological sample 
                                  types using a range of analytical techniques. 
                                  This acquisition positions EKF as a leading 
                                  'one stop' provider of diagnostic products and 
                                  services from sample collection to results. 
       In May 2021, EKF announced its strategy for delivering growth 
       to 2024 and beyond, and continuing to deliver shareholder 
       value. The strategy for growth can be summarised as: 
        *    continuing innovation in products and services in 
             Point-of-Care, Central Laboratory and Life Sciences 
             leveraging new and existing routes to market and 
        *    investment in expanded production and kitting 
             capabilities to offer a suite of diagnostic Contract 
             Manufacturing solutions to third party businesses; 
        *    expansion of CLIA Laboratories Testing offering 
             building on the acquired capabilities in ADL Health; 
        *    identify complementary earnings-enhancing 
             acquisitions with key strategic value. 
       EKF will also continue to generate enhanced shareholder value 
        *    a progressive dividend policy; and 
        *    its agreement with Mount Sinai Innovation Partners 
             ("MSIP"), which allows us advanced access to 
             innovative commercial opportunities and where we can 
             build on the ongoing successes of Renalytix plc, 
             Verici Dx plc and Trellus Health plc. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 05, 2022 02:00 ET (06:00 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Ene 2023 a Feb 2023 Haga Click aquí para más Gráficas Ekf Diagnostics.
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2022 a Feb 2023 Haga Click aquí para más Gráficas Ekf Diagnostics.